Medtronic's $2.9 Billion R&D Bet Faces Its First Real Test This Week

Medtronic logged 315-plus approvals and $2.9B R&D while its MiniMed share exchange runs to an October 9 expiry and new CPT codes wait until 2028.

Medtronic has spent the past year assembling one of the more crowded regulatory calendars in medtech — and now the market wants proof it can convert paperwork into profit.

The Irish-domiciled device maker disclosed in its fiscal 2026 Impact Report that it funneled $2.9 billion into research and development while securing more than 315 product approvals across its key markets. The same report put the company's global patient reach at over 82 million. Those headline figures arrived alongside a share price that has been drifting: the stock slipped 1.4% on Tuesday to EUR 77.36, leaving a market capitalization of EUR 98.55 billion, and it was trading at EUR 77.78 with a modest 0.8% decline in European hours on Wednesday.

A Pipeline Built for the Late 2020s

The approvals stack up across several franchises. In cardiovascular care, Medtronic's drug-coated balloon received FDA breakthrough device designation, and the company is preparing a randomized pivotal trial of roughly 400 patients to establish IN.PACT BTK in the market. European clearances for new mapping and ablation platforms — including the Affera Prism-2 mapping software and the PulseSelect ProxBox adapter — have strengthened the electrophysiology portfolio, while the VenaSeal closure system posted an 88.1% healing rate among 125 patients with venous leg ulcers, with anatomical closure at 78%.

Reimbursement, the lever that ultimately determines whether any of this generates revenue, moved in Medtronic's favor on October 1 when the American Medical Association granted Category I CPT codes for two procedures: the Altaviva system for urge incontinence and the Symplicity Spyral system for renal denervation. The new codes replace the previous Category III designations and take effect in January 2028.

That 2028 start date cuts both ways. It locks in a durable billing foundation for cardiovascular therapies, yet it also means the financial payoff sits years away while the $2.9 billion in annual development spending hits the income statement today. Bridging that gap is now the central question for investors.

MiniMed Exchange Enters Its Final Days

Running parallel to the clinical story is the separation of the diabetes unit, and it is here that the near-term calendar is tightest. Medtronic's exchange offer for MiniMed — covering up to 225,361,295 newly issued shares in a transaction valued at roughly $4 billion — entered its final valuation phase on October 5 and runs through Wednesday, with a scheduled expiry of October 9, 2026, barring an extension.

The share reaction has traced the deal's arc: the transaction triggered selling about three weeks ago, showed signs of recovery roughly a week ago, and now traders are watching the clock. Press reports point to concerns about a sluggish take-up. Should the exchange stall, the intended reduction in Medtronic's outstanding share count would come in smaller than planned — a mechanical consequence for the remaining equity rather than a verdict on the underlying business.

Where the Bulls and Bears Stand

TD Cowen reaffirmed its Buy rating on September 30 with a $110 price target, a call that rests on the argument that newly cleared devices will be adopted quickly by hospital chains and clinics, lifting margins in high-contribution therapy areas once lower-margin operations are shed.

The counterargument is one of timing and execution. Clinical programs can slip — a slower-than-planned enrollment in the 400-patient IN.PACT BTK study would push commercialization further out — and the spinoff itself absorbs significant management bandwidth. If Medtronic misses expectations on market penetration for its cardiac and vascular therapies in coming quarters, valuation multiples could stay below the sector average.

The company's own framing ties the pieces together: new clearances and expanded reimbursement structures are meant to underwrite its long-term position in strategic core fields. Whether that translates into cash is what the next few quarters will settle. Once the MiniMed exchange formally closes, the market's attention shifts entirely to the reshaped core — and to whether the pipeline can finally start paying for itself.